- Home
- TARS vs VRDN Comparison
TARS vs VRDN Comparison
Compare TARS & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- VRDN
- Stock Information
- Founded
- TARS 2016
- VRDN 2006
- Country
- TARS United States
- VRDN United States
- Employees
- TARS N/A
- VRDN N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- VRDN Medical Specialities
- Sector
- TARS Health Care
- VRDN Health Care
- Exchange
- TARS Nasdaq
- VRDN Nasdaq
- Market Cap
- TARS 1.8B
- VRDN 1.6B
- IPO Year
- TARS 2020
- VRDN N/A
- Fundamental
- Price
- TARS $53.26
- VRDN $20.82
- Analyst Decision
- TARS Strong Buy
- VRDN Strong Buy
- Analyst Count
- TARS 5
- VRDN 11
- Target Price
- TARS $54.20
- VRDN $37.63
- AVG Volume (30 Days)
- TARS 469.2K
- VRDN 1.4M
- Earning Date
- TARS 11-13-2024
- VRDN 11-12-2024
- Dividend Yield
- TARS N/A
- VRDN N/A
- EPS Growth
- TARS N/A
- VRDN N/A
- EPS
- TARS N/A
- VRDN N/A
- Revenue
- TARS $129,621,000.00
- VRDN $302,000.00
- Revenue This Year
- TARS $895.24
- VRDN $2.55
- Revenue Next Year
- TARS $73.78
- VRDN N/A
- P/E Ratio
- TARS N/A
- VRDN N/A
- Revenue Growth
- TARS 801.96
- VRDN N/A
- 52 Week Low
- TARS $18.84
- VRDN $11.40
- 52 Week High
- TARS $54.44
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- TARS 64.67
- VRDN 51.29
- Support Level
- TARS $48.45
- VRDN $17.25
- Resistance Level
- TARS $53.85
- VRDN $23.65
- Average True Range (ATR)
- TARS 2.40
- VRDN 1.05
- MACD
- TARS -0.14
- VRDN 0.12
- Stochastic Oscillator
- TARS 80.30
- VRDN 55.78
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.